Treatment of primary membranous nephropathy: where are we now?

Andrea Angioi, Nicola Lepori, Ana Coloma López, Sanjeev M Sethi, Fernando Custodio Fervenza, Antonello Pani

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In the last 10 years, basic science and clinical research have made important contributions to the understanding and management of primary membranous nephropathy (MN). The identification of antibodies directed against the M-type phospholipase A2 receptor (PLA2R) and thrombospondin type-1 domain-containing 7A protein have added a new perspective on diagnosis, monitoring the immunological activity, predicting prognosis and guiding therapy in patients with primary MN. Mounting evidence suggests that quantification and follow-up of antiPLA2R Abs levels can help in assessing prognosis and evaluate the response to treatment. The kidney disease improving global outcomes guidelines published in 2012 have not been updated. New data on the use of rituximab suggest it should be considered as a potential initial therapy in the treatment of patients with primary MN.

Original languageEnglish (US)
Pages (from-to)1-14
Number of pages14
JournalJournal of Nephrology
DOIs
StateAccepted/In press - Sep 5 2017

Fingerprint

Membranous Glomerulonephritis
Phospholipase A2 Receptors
Thrombospondin 1
Immunologic Monitoring
Immunologic Tests
Kidney Diseases
Therapeutics
Guidelines
Antibodies
Research
Proteins

Keywords

  • Glomerulopathies
  • Immunosuppression
  • Membranous glomerulonephritis
  • Renal diseases

ASJC Scopus subject areas

  • Nephrology

Cite this

Treatment of primary membranous nephropathy : where are we now? / Angioi, Andrea; Lepori, Nicola; López, Ana Coloma; Sethi, Sanjeev M; Fervenza, Fernando Custodio; Pani, Antonello.

In: Journal of Nephrology, 05.09.2017, p. 1-14.

Research output: Contribution to journalArticle

Angioi, Andrea ; Lepori, Nicola ; López, Ana Coloma ; Sethi, Sanjeev M ; Fervenza, Fernando Custodio ; Pani, Antonello. / Treatment of primary membranous nephropathy : where are we now?. In: Journal of Nephrology. 2017 ; pp. 1-14.
@article{d54cc6014872411c9dc43cbf3ad1f8d3,
title = "Treatment of primary membranous nephropathy: where are we now?",
abstract = "In the last 10 years, basic science and clinical research have made important contributions to the understanding and management of primary membranous nephropathy (MN). The identification of antibodies directed against the M-type phospholipase A2 receptor (PLA2R) and thrombospondin type-1 domain-containing 7A protein have added a new perspective on diagnosis, monitoring the immunological activity, predicting prognosis and guiding therapy in patients with primary MN. Mounting evidence suggests that quantification and follow-up of antiPLA2R Abs levels can help in assessing prognosis and evaluate the response to treatment. The kidney disease improving global outcomes guidelines published in 2012 have not been updated. New data on the use of rituximab suggest it should be considered as a potential initial therapy in the treatment of patients with primary MN.",
keywords = "Glomerulopathies, Immunosuppression, Membranous glomerulonephritis, Renal diseases",
author = "Andrea Angioi and Nicola Lepori and L{\'o}pez, {Ana Coloma} and Sethi, {Sanjeev M} and Fervenza, {Fernando Custodio} and Antonello Pani",
year = "2017",
month = "9",
day = "5",
doi = "10.1007/s40620-017-0427-5",
language = "English (US)",
pages = "1--14",
journal = "Journal of Nephrology",
issn = "1121-8428",
publisher = "Wichtig Publishing",

}

TY - JOUR

T1 - Treatment of primary membranous nephropathy

T2 - where are we now?

AU - Angioi, Andrea

AU - Lepori, Nicola

AU - López, Ana Coloma

AU - Sethi, Sanjeev M

AU - Fervenza, Fernando Custodio

AU - Pani, Antonello

PY - 2017/9/5

Y1 - 2017/9/5

N2 - In the last 10 years, basic science and clinical research have made important contributions to the understanding and management of primary membranous nephropathy (MN). The identification of antibodies directed against the M-type phospholipase A2 receptor (PLA2R) and thrombospondin type-1 domain-containing 7A protein have added a new perspective on diagnosis, monitoring the immunological activity, predicting prognosis and guiding therapy in patients with primary MN. Mounting evidence suggests that quantification and follow-up of antiPLA2R Abs levels can help in assessing prognosis and evaluate the response to treatment. The kidney disease improving global outcomes guidelines published in 2012 have not been updated. New data on the use of rituximab suggest it should be considered as a potential initial therapy in the treatment of patients with primary MN.

AB - In the last 10 years, basic science and clinical research have made important contributions to the understanding and management of primary membranous nephropathy (MN). The identification of antibodies directed against the M-type phospholipase A2 receptor (PLA2R) and thrombospondin type-1 domain-containing 7A protein have added a new perspective on diagnosis, monitoring the immunological activity, predicting prognosis and guiding therapy in patients with primary MN. Mounting evidence suggests that quantification and follow-up of antiPLA2R Abs levels can help in assessing prognosis and evaluate the response to treatment. The kidney disease improving global outcomes guidelines published in 2012 have not been updated. New data on the use of rituximab suggest it should be considered as a potential initial therapy in the treatment of patients with primary MN.

KW - Glomerulopathies

KW - Immunosuppression

KW - Membranous glomerulonephritis

KW - Renal diseases

UR - http://www.scopus.com/inward/record.url?scp=85034647271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034647271&partnerID=8YFLogxK

U2 - 10.1007/s40620-017-0427-5

DO - 10.1007/s40620-017-0427-5

M3 - Article

C2 - 28875476

AN - SCOPUS:85034647271

SP - 1

EP - 14

JO - Journal of Nephrology

JF - Journal of Nephrology

SN - 1121-8428

ER -